TABLE 3.
Characteristics of preformed DSA against the second donor.
| Total n = 45 | No DREMM n = 18 | DREMM n = 27 | P-value | |
|---|---|---|---|---|
| Locus of the preformed DSA with the maximal value, n (%) Class I A B Cw Class II DR DQB DQA |
31 (69) 8 (26) 8 (26) 15 (48) 14 (31) 8 (57) 4 (29) 2 (14) |
14 (78) 3 (21) 3 (21) 8 (57) 4 (22) 3 (75) 1 (25) 0 (0) |
17 (63) 5 (29) 5 (29) 7 (41) 10 (37) 5 (50) 3 (30) 2 (20) |
0.29 |
| MFImax value of the preformed DSA, median (IQR) | 4,813 (1,566–11,667) | 1,676 (1,146–6,407) | 8,326 (2,880–12,928) | 0.01 |
| Sum of DSA MFI, median (IQR) | 7,328 (2,667–16,352) | 2,482 (1,292–6,787) | 14,249 (7,163–24,752) | <0.001 |
| Persistence of the preformed DSA with the maximal value, n (%) At 3 months post-transplant a At 12 months post-transplant b |
26 (59) 18 (43) |
7 (39) 5 (28) |
19 (73) 13 (54) |
0.02 0.09 |
| Time between 1st and 2nd transplant, years, median (IQR) | 12 (9–16) | 11 (9–14) | 12 (10–17) | 0.57 |
| History of transplantectomy, n (%) | 21 (46.7%) | 6 (33.3) | 15 (55.6) | 0.14 |
DSA, donor-specific antibody; DREMM, donor-specific antibody targeting a repeated antibody-verified eplet mismatch; MFI, mean fluorescence intensity; Sum of MFI, sum of the MFI of each DSA the day of the maximal MFI of the preformed DSA.
a
missing value for one patient in the DREMM group.
b
missing values for three patients in the DREMM group.